iRhythm Holdings (IRTC) risk factors, FY2024 10-K

Risks Related to Our Industry, Business and Operations

1. 01If reimbursement or other payment for our Zio Services is reduced or modified in the United States or in our international markets, including through cost containment measures or changes to policies with respect to coding, coverage, and pricing, our business could suffer
2. 02If we are unable to expand the number of third-party commercial payors with which we contract or expand coverage for existing third-party commercial payors, our commercial success could be impacted
3. 03Our revenue relies on our Zio Services, which are currently our only offerings. If our Zio Services or future service offerings fail to gain, or lose, market acceptance, our business will suffer
4. 04Audits or denials of our claims by government agencies or payors could expose us to recoupment, regulatory scrutiny, and penalties
5. 05We may not be able to obtain additional marketing authorizations in a timely fashion, or at all, which could harm our ability to introduce new or enhanced products in a timely manner and to meet market expectations for the provision of the services, which in turn could harm our future growth
6. 06If we are unable to keep up with demand for our Zio Services, our revenue could be impaired, market acceptance for our Zio Services could be harmed, and physicians may instead order our competitors’ services
7. 07We depend on third-party vendors for the supply and manufacture of certain components of our Zio Systems, as well as for other aspects of our operations
8. 08We have incorporated and continue to work to further incorporate AI into our products, services, and internal operations. Implementation of artificial intelligence and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business
9. 09Our ability to compete depends on our ability to innovate successfully
10. 10We have entered into in the past, and may explore or enter into in the future, development or collaboration agreements with third parties. These development and collaboration agreements may not result in the development of commercially viable devices or the generation of significant future revenues
11. 11International expansion of our business exposes us to market, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States
12. 12Our success depends on our ability to attract and retain senior management and key personnel
13. 13Our continued rapid growth could strain our personnel resources and infrastructure, and if we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed
14. 14Failure to receive the Zio System patches used for the provision of the Zio Services we provide may result in a loss of capital as well as revenue where the receipt of returned devices and processing of data retrieved from returned devices is required to provide our Zio Services
15. 15We may face risks associated with acquisitions of companies, products, and technologies and our business could be harmed if we are unable to address these risks

Risks Related to Healthcare Regulatory Matters

1. 16If we fail to comply with medical device, healthcare, and other governmental regulations, we could face substantial penalties and our business, results of operations, and financial condition could be adversely affected
2. 17Changes in applicable laws or regulations or the interpretation or enforcement policies of regulators governing our IDTFs and Zio Services may constrain or require us to restructure our operations or adapt certain business strategies which may harm our revenue and operating results
3. 18Our business could be negatively impacted by changes in the United States political environment
4. 19As a Medicare-enrolled IDTF, we are prohibited from directly soliciting patients for diagnostic medical procedures. While we can engage in general marketing initiatives, consistent with applicable law, we cannot make telephone, computer, and in-person contacts for the purpose of soliciting business for our IDTF

Risks Related to Financial and Accounting Matters

1. 20In the future we may identify additional material weaknesses or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our consolidated financial statements or cause us to fail to meet our periodic reporting obligations
2. 21Our financial results may fluctuate significantly from quarter-to-quarter and may not fully reflect the underlying performance of our business
3. 22We have a history of operating losses and may not achieve or sustain profitability in the future
4. 23We may require additional capital to support the growth of our business, and this capital might not be available on acceptable terms, if at all
5. 24Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations which could subject our business to higher tax liability

Risks Related to Other Legal and Regulatory Matters

1. 25We are subject to legal proceedings and government investigations that could adversely affect our business, financial condition, and results of operations
2. 26Compliance with requirements of being a public company may strain our resources and divert management’s attention
3. 27We could be subject to changes in our tax rates, new U.S. or international tax legislation, or additional tax liabilities
4. 28We may be liable for contamination or other harm caused by materials that we handle, and changes in environmental regulations could cause us to incur additional expense

Risks Related to Intellectual Property

1. 29Our inability to adequately protect our intellectual property could allow our competitors and others to produce devices and offer services based on our technology, which could substantially impair our ability to compete

Risks Related to Privacy and Security

1. 30Cyber-attacks aimed at accessing our devices and services, or related devices and services, and modifying or using them in a way inconsistent with our FDA marketing authorizations and regulatory certifications in the EU and the UK, could create risks to patients

Risks Related to Our Common Stock

1. 31If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline
2. 32Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substantial losses for investors
3. 33Anti-takeover effects of our charter documents and Delaware law could make a merger, tender offer, or proxy contest difficult, thereby depressing the trading price of our common stock
4. 34Moreover, Section 203 of the DGCL may discourage, delay, or prevent a change of control of our company. Section 203 imposes certain restrictions on mergers, business combinations, and other transactions between us and holders of 15% or more of our common stock
5. 35We do not intend to pay dividends for the foreseeable future

Risks Related to Our Debt

1. 36Our indebtedness could adversely affect our financial health and our ability to respond to changes in our business
2. 37Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our indebtedness
3. 38The capped call transactions may affect the value of our common stock
4. 39We are subject to counterparty risk with respect to the capped call transactions
5. 40Conversion of the 2029 Notes will, to the extent we deliver shares upon conversion of such 2029 Notes, dilute the ownership interest of existing stockholders, including holders who had previously converted their 2029 Notes, or may otherwise depress our stock price
6. 41The conditional conversion feature of the 2029 Notes, if triggered, may adversely affect our financial condition and operating results
7. 42The accounting method for convertible debt securities that may be settled in cash, such as the 2029 Notes, could have a material effect on our reported financial results
8. 43We may be impacted by domestic and global economic and political conditions, as well as natural disasters, pandemics, and other catastrophic events, which could adversely affect our business, financial condition, or results of operations
9. 44Environmental, social, and corporate governance (“ESG”) regulations, policies, and provisions may make our supply chain more complex and may adversely affect our relationships with customers